Respiratorius

Executive Summary

Respiratorius AB is a Swedish biopharmaceutical company dedicated to developing innovative therapies for aggressive cancers, with a primary focus on diffuse large B-cell lymphoma (DLBCL). The company's lead asset, VAL001, has completed a Phase I/IIa clinical trial, demonstrating initial safety and efficacy signals. By pursuing early-stage collaborations with global partners, Respiratorius aims to mitigate financial and operational risks while accelerating the path to market. The company's lean structure and targeted approach position it well in the competitive oncology landscape, though it remains at an early development stage with no approved products or revenue.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase II clinical trial for VAL00170% success
• TBDAnnouncement of strategic partnership for development or commercialization50% success
• TBDPublication of full Phase I/IIa results in a peer-reviewed journal80% success